Hem
”Magiska svampar” i ett laboratorium i Nederländerna. (PETER DEJONG / AP)

”Magiska svampar” testas för att behandla depression

Den verksamma substansen i ”magiska svampar”, psilocybin, ska nu för första gången testas för att behandla deprimerade patienter i Sverige. Det skriver Svenska Dagbladet.

I vår ska 30 personer delta i en fas II-studie vid Karolinska institutet, där hälften kommer att få placebo och den andra hälften psilocybin.

– Runt en tredjedel av de drabbade blir inte hjälpta av de behandlingar som finns i dag – så det finns stora skäl att söka fler lösningar, säger Johan Lundberg, docent vid institutionen för klinisk neurovetenskap vid Karolinska, som är ansvarig för studien.

Intresset för psilocybin har ökat de senaste tio åren och några studier som har publicerats har visat att ämnen kan ha effekt mot bland annat depression och ångest hos cancerpatienter.

bakgrund
 
Psilocybin
Wikipedia (en)
Psilocybin ( sy-lə-SY-bin) is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungus. The most potent are members of the genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. As a prodrug, psilocybin is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of LSD, mescaline, and DMT. In general, the effects include euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, and spiritual experiences, and can also include possible adverse reactions such as nausea and panic attacks. Imagery found on prehistoric murals and rock paintings of modern-day Spain and Algeria suggests that human usage of psilocybin mushrooms predates recorded history. In Mesoamerica, the mushrooms had long been consumed in spiritual and divinatory ceremonies before Spanish chroniclers first documented their use in the 16th century. In 1959, the Swiss chemist Albert Hofmann isolated the active principle psilocybin from the mushroom Psilocybe mexicana. Hofmann's employer Sandoz marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic psychotherapy. Although the increasingly restrictive drug laws of the late 1960s curbed scientific research into the effects of psilocybin and other hallucinogens, its popularity as an entheogen (spirituality-enhancing agent) grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms. The intensity and duration of the effects of psilocybin are variable, depending on species or cultivar of mushrooms, dosage, individual physiology, and set and setting, as was shown in experiments led by Timothy Leary at Harvard University in the early 1960s. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. The mind-altering effects of psilocybin typically last from two to six hours, although to individuals under the influence of psilocybin, the effects may seem to last much longer, since the drug can distort the perception of time. Psilocybin has a low toxicity and a low harm potential. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and it has been classified as a scheduled drug by many national drug laws. Psilocybin is currently being researched for its effect on depression, anxiety and other psychiatric conditions.
Omni är politiskt obundna och oberoende. Vi strävar efter att ge fler perspektiv på nyheterna. Har du frågor eller synpunkter kring vår rapportering? Kontakta redaktionen